Unmet need in rheumatoid arthritis

  • Research type

    Research Study

  • Full title

    Patient survey of unmet need and burden of illness in rheumatoid arthritis

  • IRAS ID

    179147

  • Contact name

    Rob Arbuckle

  • Contact email

    rob.arbuckle@adelphivalues.com

  • Sponsor organisation

    Pfizer Ltd

  • Clinicaltrials.gov Identifier

    15/SC/0393, South Central - Hampshre A

  • Duration of Study in the UK

    0 years, 6 months, 0 days

  • Research summary

    This is a mixed-methods, non-interventional study to identify any unmet need in patients with rheumatoid arthritis and to further understand the burden of rheumatoid arthritis on patients who have had an inadequate response or shown intolerance to first line therapies. The study is sponsored by Pfizer and is being conducted by Adelphi Values, a health outcomes consultancy.

    Qualitative interviews will be conducted with patients (n=10) and clinicians (n=2) in the UK. Similar interviews will also be conducted in France, Germany, Spain and Italy with the same sample size in each country. Patient and clinicians will be asked to provide written informed consent before participating in any study related activities and before any of the patients’ medical information is shared with Adelphi Values. With patient consent, some clinical and demographic information will also be collected about the patient. Before the interview, patients will complete two short questionnaires (HAQ-DI and EQ-5D) to assess their level of physical functioning. The qualitative interview will last approximately 60-minutes and will be conducted by a trained interviewer at a convenient location. It will be made clear to all patients and clinicians that they are free to talk as much or as little as they like and are free to withdraw from the study at any point. During the interview patients will be asked about their experience of rheumatoid arthritis, how it affects their physical functioning and emotional wellbeing and their experience with arthritis treatments. Similarly, clinicians will be asked about the patient burden of arthritis and the effectiveness of different treatments in their clinical experience. Patients will be compensated for their time to take part in the study.

  • REC name

    North East - Newcastle & North Tyneside 1 Research Ethics Committee

  • REC reference

    15/NE/0233

  • Date of REC Opinion

    30 Jun 2015

  • REC opinion

    Favourable Opinion